Lijst publicaties

1: Sprooten J, Coosemans A, Garg AD. A first-in-class, non-invasive,
immunodynamic biomarker approach for precision immuno-oncology. Oncoimmunology.
2022 Jan 10;11(1):2024692. doi: 10.1080/2162402X.2021.2024692. PMID: 35036075;
PMCID: PMC8757472.

2: De Bruyn C, Ceusters J, Landolfo C, Baert T, Thirion G, Claes S,
Vankerckhoven A, Wouters R, Schols D, Timmerman D, Vergote I, Coosemans A. Neo-
Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-
Line Treatment for Ovarian Cancer. Cancers (Basel). 2021 Nov 24;13(23):5899.
doi: 10.3390/cancers13235899. PMID: 34885008; PMCID: PMC8656504.

3: El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas
JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F,
Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria
P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL,
Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa
N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A,
Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S,
Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl
S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA,
Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R,
Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-
Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report
from The International Immuno-Oncology Biomarker Working Group. NPJ Breast
Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355;
PMCID: PMC8636568.

4: Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters
R, Laureano RS, Baert T, Boon L, Landolfo C, Testa AC, Fischerova D, Van
Holsbeke C, Bourne T, Chiappa V, Froyman W, Schols D, Agostinis P, Timmerman D,
Tejpar S, Vergote I, Coosemans A, Garg AD. Peripherally-driven myeloid NFkB and
IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in
ovarian cancer. J Immunother Cancer. 2021 Nov;9(11):e003609. doi:
10.1136/jitc-2021-003609. PMID: 34795003; PMCID: PMC8603275.

5: Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek
R. Immunological configuration of ovarian carcinoma: features and impact on
disease outcome. J Immunother Cancer. 2021 Oct;9(10):e002873. doi:
10.1136/jitc-2021-002873. PMID: 34645669; PMCID: PMC8515436.

6: Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T,
Van Nieuwenhuysen E, Han S, Van den Broeck A, Coosemans A, Van Rompuy AS,
Lambrechts D, Vergote I. High-grade serous tubo-ovarian cancer refined with
single-cell RNA sequencing: specific cell subtypes influence survival and
determine molecular subtype classification. Genome Med. 2021 Jul 9;13(1):111.
doi: 10.1186/s13073-021-00922-x. PMID: 34238352; PMCID: PMC8268616.

7: Vanherp L, Govaerts K, Riva M, Poelmans J, Coosemans A, Lagrou K, Gsell W,
Vande Velde G, Himmelreich U. CryptoCEST: A promising tool for spatially
resolved identification of fungal brain lesions and their differentiation from
brain tumors with MRI. Neuroimage Clin. 2021;31:102737. doi:
10.1016/j.nicl.2021.102737. Epub 2021 Jun 24. PMID: 34225021; PMCID: PMC8261661.

8: Vankerckhoven A, Baert T, Riva M, De Bruyn C, Thirion G, Vandenbrande K,
Ceusters J, Vergote I, Coosemans A. Type of chemotherapy has substantial effects
on the immune system in ovarian cancer. Transl Oncol. 2021 Jun;14(6):101076.
doi: 10.1016/j.tranon.2021.101076. Epub 2021 Mar 23. PMID: 33770618; PMCID:
PMC8022256.

9: Wouters R, Bevers S, Riva M, De Smet F, Coosemans A. Immunocompetent Mouse
Models in the Search for Effective Immunotherapy in Glioblastoma. Cancers
(Basel). 2020 Dec 23;13(1):19. doi: 10.3390/cancers13010019. PMID: 33374542;
PMCID: PMC7793150.

10: Riva M, Wouters R, Sterpin E, Giovannoni R, Boon L, Himmelreich U, Gsell W,
Van Ranst M, Coosemans A. Radiotherapy, Temozolomide, and Antiprogrammed Cell
Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental
High-Grade Glioma. Neurosurgery. 2021 Jan 13;88(2):E205-E215. doi:
10.1093/neuros/nyaa421. PMID: 33289503.

11: Riva M, Wouters R, Nittner D, Ceuster J, Sterpin E, Giovannoni R,
Himmelreich U, Gsell W, Van Ranst M, Coosemans A. Radiation dose-escalation and
dose-fractionation modulate the immune microenvironment, cancer stem cells and
vasculature in experimental high-grade gliomas. J Neurosurg Sci. 2020 Oct 15.
doi: 10.23736/S0390-5616.20.05060-2. Epub ahead of print. PMID: 33056947.

12: Landolfo C, Achten ETL, Ceusters J, Baert T, Froyman W, Heremans R,
Vanderstichele A, Thirion G, Van Hoylandt A, Claes S, Oosterlynck J, Van Rompuy
AS, Schols D, Billen J, Van Calster B, Bourne T, Van Gorp T, Vergote I,
Timmerman D, Coosemans A. Assessment of protein biomarkers for preoperative
differential diagnosis between benign and malignant ovarian tumors. Gynecol
Oncol. 2020 Dec;159(3):811-819. doi: 10.1016/j.ygyno.2020.09.025. Epub 2020 Sep
29. PMID: 32994054.

13: Van Calster B, Valentin L, Froyman W, Landolfo C, Ceusters J, Testa AC,
Wynants L, Sladkevicius P, Van Holsbeke C, Domali E, Fruscio R, Epstein E,
Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Coccia ME,
Guerriero S, Deo N, Jokubkiene L, Savelli L, Fischerová D, Czekierdowski A,
Kaijser J, Coosemans A, Scambia G, Vergote I, Bourne T, Timmerman D. Validation
of models to diagnose ovarian cancer in patients managed surgically or
conservatively: multicentre cohort study. BMJ. 2020 Jul 30;370:m2614. doi:
10.1136/bmj.m2614. PMID: 32732303; PMCID: PMC7391073.

14: Belderbos S, González-Gómez MA, Cleeren F, Wouters J, Piñeiro Y, Deroose CM,
Coosemans A, Gsell W, Bormans G, Rivas J, Himmelreich U. Simultaneous in vivo
PET/MRI using fluorine-18 labeled Fe₃O₄@Al(OH)₃
nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell
distribution. EJNMMI Res. 2020 Jun 30;10(1):73. doi: 10.1186/s13550-020-00655-9.
PMID: 32607918; PMCID: PMC7326875.

15: Bulle A, Dekervel J, Deschuttere L, Nittner D, Libbrecht L, Janky R,
Plaisance S, Topal B, Coosemans A, Lambrechts D, Van Cutsem E, Verslype C, van
Pelt J. Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the
Stroma of Pancreatic Cancer. Transl Oncol. 2020 Mar;13(3):100743. doi:
10.1016/j.tranon.2020.01.004. Epub 2020 Mar 4. PMID: 32145636; PMCID:
PMC7058407.

16: Vankerckhoven A, Wouters R, Mathivet T, Ceusters J, Baert T, Van Hoylandt A,
Gerhardt H, Vergote I, Coosemans A. Opposite Macrophage Polarization in
Different Subsets of Ovarian Cancer: Observation from a Pilot Study. Cells. 2020
Jan 27;9(2):305. doi: 10.3390/cells9020305. PMID: 32012728; PMCID: PMC7072171.

17: De Bruyn C, Baert T, Van den Bosch T, Coosemans A. Circulating Transcripts
and Biomarkers in Uterine Tumors: Is There a Predictive Role? Curr Oncol Rep.
2020 Jan 29;22(2):12. doi: 10.1007/s11912-020-0864-5. PMID: 31997106.

18: Coosemans AN, Baert T, D'Heygere V, Wouters R, DE Laet L, VAN Hoylandt A,
Thirion G, Ceusters J, Laenen A, Vandecaveye V, Vergote I. Increased
Immunosuppression Is Related to Increased Amounts of Ascites and Inferior
Prognosis in Ovarian Cancer. Anticancer Res. 2019 Nov;39(11):5953-5962. doi:
10.21873/anticanres.13800. PMID: 31704820.

19: Coosemans A, Baert T, Ceusters J, Busschaert P, Landolfo C, Verschuere T,
Van Rompuy AS, Vanderstichele A, Froyman W, Neven P, Van Calster B, Vergote I,
Timmerman D. Myeloid-derived suppressor cells at diagnosis may discriminate
between benign and malignant ovarian tumors. Int J Gynecol Cancer. 2019
Nov;29(9):1381-1388. doi: 10.1136/ijgc-2019-000521. PMID: 31685557.

20: Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S,
Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell
vaccination for cancer immunotherapy. Oncoimmunology. 2019 Jul
18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. PMID: 31646087; PMCID:
PMC6791419.

21: Riva M, Wouters R, Weerasekera A, Belderbos S, Nittner D, Thal DR, Baert T,
Giovannoni R, Gsell W, Himmelreich U, Van Ranst M, Coosemans A. CT-2A
neurospheres-derived high-grade glioma in mice: a new model to address tumor
stem cells and immunosuppression. Biol Open. 2019 Sep 12;8(9):bio044552. doi:
10.1242/bio.044552. PMID: 31511246; PMCID: PMC6777368.

22: Glorie N, Baert T, VAN DEN Bosch T, Coosemans AN. Circulating Protein
Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas. Anticancer Res.
2019 Aug;39(8):3981-3989. doi: 10.21873/anticanres.13553. PMID: 31366479.

23: Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G,
Mathivet T, Vergote I, Coosemans A. Myeloid Derived Suppressor Cells: Key
Drivers of Immunosuppression in Ovarian Cancer. Front Immunol. 2019 Jun
4;10:1273. doi: 10.3389/fimmu.2019.01273. PMID: 31214202; PMCID: PMC6558014.

24: Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S,
Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I. Combining
conventional therapy with immunotherapy: A risky business? Eur J Cancer. 2019
May;113:41-44. doi: 10.1016/j.ejca.2019.02.014. Epub 2019 Apr 6. PMID: 30965214.

25: Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, Van
Holsbeke C, Domali E, Fruscio R, Epstein E, Dos Santos Bernardo MJ, Franchi D,
Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Hochberg L, Coccia ME,
Guerriero S, Deo N, Jokubkiene L, Kaijser J, Coosemans A, Vergote I, Verbakel
JY, Bourne T, Van Calster B, Valentin L, Timmerman D. Risk of complications in
patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim
analysis of a multicentre, prospective, cohort study. Lancet Oncol. 2019
Mar;20(3):448-458. doi: 10.1016/S1470-2045(18)30837-4. Epub 2019 Feb 5. PMID:
30737137.

26: Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van
Nieuwenhuysen E, Vergote I, Coosemans A. Influence of CA125, platelet count and
neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
Gynecol Oncol. 2018 Jul;150(1):31-37. doi: 10.1016/j.ygyno.2018.05.004. Epub
2018 May 9. PMID: 29751991.

27: Landolfo C, Valentin L, Franchi D, Van Holsbeke C, Fruscio R, Froyman W,
Sladkevicius P, Kaijser J, Ameye L, Bourne T, Savelli L, Coosemans A, Testa A,
Timmerman D. Differences in ultrasound features of papillations in unilocular-
solid adnexal cysts: a retrospective international multicenter study. Ultrasound
Obstet Gynecol. 2018 Aug;52(2):269-278. doi: 10.1002/uog.18951. PMID: 29119698.

28: Baert T, Garg AD, Agostinis P, Vergote I, Coosemans A. Orientation of
Preclinical Research in Ovarian Cancer. Int J Gynecol Cancer. 2017
Oct;27(8):1579-1586. doi: 10.1097/IGC.0000000000001053. PMID: 28945211.

29: Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-
Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila
J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer
RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé
E, Hermans E, Moerman P, Bosse T, Amant F. Potential Targets' Analysis Reveals
Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for
Uterine Leiomyosarcomas-an ENITEC Group Initiative. Clin Cancer Res. 2017 Mar
1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149. PMID: 28232476.

30: Baert T, Vergote I, Coosemans A. Ovarian cancer and the immune system.
Gynecol Oncol Rep. 2017 Jan 6;19:57-58. doi: 10.1016/j.gore.2017.01.002. PMID:
28127584; PMCID: PMC5247278.

31: Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E,
Leunen K, Neven P, Amant F, Mahner S, Braicu EI, Zeilinger R, Coosemans A,
Timmerman D, Lambrechts D, Vergote I. Chromosomal Instability in Cell-Free DNA
as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with
Adnexal Masses. Clin Cancer Res. 2017 May 1;23(9):2223-2231. doi:
10.1158/1078-0432.CCR-16-1078. Epub 2016 Nov 14. PMID: 27852697.

32: Baert T, Garg AD, Vindevogel E, VAN Hoylandt A, Verbist G, Agostinis P,
Vergote I, Coosemans AN. In Vitro Generation of Murine Dendritic Cells for
Cancer Immunotherapy: An Optimized Protocol. Anticancer Res. 2016
Nov;36(11):5793-5801. doi: 10.21873/anticanres.11163. PMID: 27793901.

33: Vindevogel E, Baert T, VAN Hoylandt A, Verbist G, Vande Velde G, Garg AD,
Agostinis P, Vergote I, Coosemans AN. The Use of Toll-like Receptor 4 Agonist to
Reshape the Immune Signature in Ovarian Cancer. Anticancer Res. 2016
Nov;36(11):5781-5792. doi: 10.21873/anticanres.11162. PMID: 27793900.

34: Guerriero S, Van Calster B, Somigliana E, Ajossa S, Froyman W, De Cock B,
Coosemans A, Fischerová D, Van Holsbeke C, Alcazar JL, Testa AC, Valentin L,
Bourne T, Timmerman D. Age-related differences in the sonographic
characteristics of endometriomas. Hum Reprod. 2016 Aug;31(8):1723-31. doi:
10.1093/humrep/dew113. Epub 2016 Jun 9. PMID: 27282774.

35: Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van
Gool SW, Vergote I, Amant F. mRNA Electroporation of Dendritic Cells with WT1,
Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70). Methods Mol Biol.
2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18. PMID: 27236806.

36: Coosemans A, Decoene J, Baert T, Laenen A, Kasran A, Verschuere T, Seys S,
Vergote I. Immunosuppressive parameters in serum of ovarian cancer patients
change during the disease course. Oncoimmunology. 2015 Dec 21;5(4):e1111505.
doi: 10.1080/2162402X.2015.1111505. PMID: 27141394; PMCID: PMC4839325.

37: Baert T, Storme N, Van Nieuwenhuysen E, Uyttebroeck A, Van Damme N, Vergote
I, Coosemans A. Ovarian cancer in children and adolescents: A rare disease that
needs more attention. Maturitas. 2016 Jun;88:3-8. doi:
10.1016/j.maturitas.2016.03.003. Epub 2016 Mar 8. PMID: 27105689.

38: Froyman W, Landolfo C, Amant F, Van den Bosch T, Vergote I, Coosemans A,
Testa A, Valentin L, Bourne T, Calster BV, Timmerman D. Morcellation and risk of
malignancy in presumed ovarian fibromas/fibrothecomas. Lancet Oncol. 2016
Mar;17(3):273-274. doi: 10.1016/S1470-2045(16)00022-X. Epub 2016 Mar 2. PMID:
26972853.

39: Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A.
The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for
ovarian cancer. J Immunother Cancer. 2015 Dec 15;3:57. doi:
10.1186/s40425-015-0102-0. PMID: 26676113; PMCID: PMC4678634.

40: Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM,
Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher
D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab
J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G,
Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino
N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ,
Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van
den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P. Molecular and
Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol.
2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. PMID: 26635802; PMCID:
PMC4653610.

41: Coosemans A, Baert T, Vergote I. A view on dendritic cell immunotherapy in
ovarian cancer: how far have we come? Facts Views Vis Obgyn. 2015;7(1):73-8.
PMID: 25897374; PMCID: PMC4402447.

42: Baert T, Timmerman D, Vergote I, Coosemans A. Immunological parameters as a
new lead in the diagnosis of ovarian cancer. Facts Views Vis Obgyn.
2015;7(1):67-72. PMID: 25897373; PMCID: PMC4402445.

43: Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW.
Dendritic cell immunotherapy in uterine cancer. Hum Vaccin Immunother.
2014;10(7):1822-7. doi: 10.4161/hv.28716. PMID: 25424788; PMCID: PMC4186030.

44: Coosemans A, Vergote I, Van Gool SW. Wilms' tumor gene 1 immunotherapy in
pelvic gynecological malignancies. Expert Rev Clin Immunol. 2014
Jun;10(6):705-11. doi: 10.1586/1744666X.2014.910119. Epub 2014 May 2. PMID:
24784346.

45: Coosemans A, Vergote I, Van Gool SW. Dendritic cell-based immunotherapy in
ovarian cancer. Oncoimmunology. 2013 Dec 1;2(12):e27059. doi:
10.4161/onci.27059. Epub 2013 Nov 6. PMID: 24501688; PMCID: PMC3913669.

46: Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman
ZN, Vergote I, Amant F, VAN Gool SW. Wilms' Tumor Gene 1 (WT1)--loaded dendritic
cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
Anticancer Res. 2013 Dec;33(12):5495-500. PMID: 24324087.

47: Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman
Z, Vergote I, Amant F, Van Gool SW. Immunological response after WT1 mRNA-loaded
dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer
Res. 2013 Sep;33(9):3855-9. PMID: 24023319.

48: Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D,
Tomlinson I, Yu H, Lambrechts D, Dörk T, Goodman MT, Zheng Y, Salvesen HB, Bao
PP, Amant F, Beckmann MW, Coenegrachts L, Coosemans A, Dubrowinskaja N, Dunning
A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K,
Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK,
Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng
W, Shu XO. Polymorphisms in inflammation pathway genes and endometrial cancer
risk. Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):216-23. doi:
10.1158/1055-9965.EPI-12-0903. Epub 2012 Dec 5. PMID: 23221126; PMCID:
PMC3677562.

49: Long J, Zheng W, Xiang YB, Lose F, Thompson D, Tomlinson I, Yu H, Wentzensen
N, Lambrechts D, Dörk T, Dubrowinskaja N, Goodman MT, Salvesen HB, Fasching PA,
Scott RJ, Delahanty R, Zheng Y, O'Mara T, Healey CS, Hodgson S, Risch H, Yang
HP, Amant F, Turmanov N, Schwake A, Lurie G, Trovik J, Beckmann MW, Ashton K, Ji
BT, Bao PP, Howarth K, Lu L, Lissowska J, Coenegrachts L, Kaidarova D, Dürst M,
Thompson PJ, Krakstad C, Ekici AB, Otton G, Shi J, Zhang B, Gorman M, Brinton L,
Coosemans A, Matsuno RK, Halle MK, Hein A, Proietto A, Cai H, Lu W, Dunning A,
Easton D, Gao YT, Cai Q, Spurdle AB, Shu XO. Genome-wide association study
identifies a possible susceptibility locus for endometrial cancer. Cancer
Epidemiol Biomarkers Prev. 2012 Jun;21(6):980-7. doi:
10.1158/1055-9965.EPI-11-1160. Epub 2012 Mar 16. PMID: 22426144; PMCID:
PMC3372671.

50: Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for
uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):257-66.
doi: 10.1016/j.bpobgyn.2011.08.002. Epub 2011 Nov 9. PMID: 22078749.

51: Coosemans A, Van Calster B, Verbist G, Moerman P, Vergote I, Van Gool SW,
Amant F. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine
sarcoma. Int J Gynecol Cancer. 2011 Feb;21(2):302-8. doi:
10.1097/IGC.0b013e318207cab5. PMID: 21734473.

52: Coosemans A. Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.
Facts Views Vis Obgyn. 2011;3(2):89-99. PMID: 24753854; PMCID: PMC3987486.

53: Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van
Gool SW. Immunological response after therapeutic vaccination with WT1 mRNA-
loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res. 2010
Sep;30(9):3709-14. PMID: 20944158.

54: Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical
management of uterine sarcomas. Lancet Oncol. 2009 Dec;10(12):1188-98. doi:
10.1016/S1470-2045(09)70226-8. PMID: 19959075.

55: Amant F, Coosemans A, Renard V, Everaert E, Vergote I. Clinical outcome of
ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five
patients and a review of the literature. Int J Gynecol Cancer. 2009
Feb;19(2):245-8. doi: 10.1111/IGC.0b013e31819c0f59. PMID: 19396002.

56: Coosemans A, Van Hove T, Verbist G, Moons L, Neven P, Moerman P, Vergote I,
Van Gool SW, Amant F. Wilms' tumour gene 1 (WT1) positivity in endothelial cells
surrounding epithelial uterine tumours. Histopathology. 2009 Feb;54(3):384-7.
doi: 10.1111/j.1365-2559.2008.03213.x. PMID: 19236519.

57: Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW,
Amant F. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol. 2008
Dec;111(3):502-8. doi: 10.1016/j.ygyno.2008.08.032. Epub 2008 Oct 16. PMID:
18929401.

58: Coosemans A, Moerman P, Vergote I, Koninckx PR, Van Gool SW, Amant F. Wilms'
tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: a pilot
study. Fertil Steril. 2009 Apr;91(4 Suppl):1441-4. doi:
10.1016/j.fertnstert.2008.06.042. Epub 2008 Aug 22. PMID: 18722603.

59: Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R,
Schelfhout V, de Jonge E, Dalle I, Jacomen G, Cassiman JJ, Moerman P, Vergote I,
Amant F. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J
Cancer. 2007 Jul;43(10):1630-7. doi: 10.1016/j.ejca.2007.04.008. Epub 2007 May
24. PMID: 17531467.